Skip to main content
Print Save

Enspryng Prices, Coupons and Patient Assistance Programs

Enspryng (satralizumab) is a member of the interleukin inhibitors drug class and is commonly used for Neuromyelitis Optica.

The cost for Enspryng subcutaneous solution (120 mg/mL) is around $17,400 for a supply of 1 milliliter(s), depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.

Enspryng prices

Subcutaneous Solution

Enspryng Coupons, Copay Cards and Rebates

Enspryng offers may be in the form of a printable coupon, rebate, savings or copay card, trial offer, or free samples. Some offers may be printed right from a website, others require registration, completing a questionnaire, or obtaining a sample from the doctor's office.

Drugs.com Printable Discount Card

The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.

Print Free Discount Card

Note: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.

Enspryng Co-pay Program: Eligible commercially insured patients may pay as little as $5 per 30-day supply; maximum savings of $20,000 per calendar year; for additional information contact the program at 844-677-7964.

Applies to:
Enspryng
Number of uses:
12 times within calendar year

Form more information phone: 844-677-7964 or Visit website

Enspryng Co-pay Program Reimbursement Request Form: Eligible commercially insured patients may apply for reimbursement after paying their provider directly for treatment; for additional information contact the program at 800-636-0373.

Applies to:
Enspryng
Number of uses:
One rebate per prescription fill

Form more information phone: 800-636-0373 or Visit website

Patient Assistance & Copay Programs for Enspryng

Patient assistance programs (PAPs) are usually sponsored by pharmaceutical companies and provide free or discounted medicines and copay programs to low income or uninsured and under-insured people who meet specific guidelines. Eligibility requirements vary for each program.

Provider: Patient Access Network Foundation (PAN)

Elligibility requirements:
  1. *See Additional Information section below
  2. Between 400-500% of FPL
  3. FDA Approved Diagnosis - See Program Website for Details
  4. Must reside and receive treatment in US
  5. *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
Applicable drugs:
  • Enspryng (satralizumab-mwge) Injection; Subcutaneous

More information please phone: 866-316-7263 Visit Website

Provider: Genentech Patient Foundation

Elligibility requirements:
  1. Uninsured or Underinsured with no prescription coverage for needed medication
  2. Based on FPL
  3. Medically appropriate condition/diagnosis
  4. Must be treated by US licensed healthcare provider
  5. The Genentech Access to Care Foundation is now the Genentech Patient Foundation. Eligibility determined on a case-by-case basis. Call for most recent medications as the list is subject to change. This program may provide a Bridge Program for eligible patients who experience a delay, temporary loss, or change in coverage. Contact program for details.
Applicable drugs:
  • Enspryng (satralizumab-mwge) Injection; Subcutaneous

More information please phone: 888-941-3331   or 866-422-2377   Visit Website

Provider: Genentech Access Solutions: Enspryng

Elligibility requirements:
  1. Determined case by case
  2. Based on FPL
  3. FDA-approved diagnosis
  4. Must be residing in the US or US territory
  5. Eligibility determined on a case-by-case basis. Contact program for details. Co-payment assistance, and patient assistance programs are available for eligible patients.
Applicable drugs:
  • Enspryng (satralizumab-mwge) Injection; Subcutaneous

More information please phone: 844-677-7964   or 866-422-2377   Visit Website